REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2019.06.09 | 19:00 | Permanent Information Releases / General Company News

puce Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments - HTML (w)

2019.06.09 | 19:00 | Permanent Information Releases / General Company News

puce Les résultats de phase III de Soliqua® montrent une baisse significative de la glycémie sanguine comparativement à des traitements par agoniste des récepteurs GLP-1 - HTML (w)

2019.06.07 | 07:00 | Permanent Information Releases / Appointments

puce Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer - HTML (w)

2019.06.07 | 07:00 | Permanent Information Releases / Appointments

puce Paul Hudson succèdera à Olivier Brandicourt comme Directeur Général - HTML (w)

2019.06.02 | 16:45 | Permanent Information Releases / General Company News

puce Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma - HTML (w)

2019.06.02 | 16:45 | Permanent Information Releases / General Company News

puce L'essai de phase III de l'isatuximab combiné au pomalidomide et à la dexaméthasone a permis d'obtenir une réduction de 40 % du risque de progression ou de décès chez des patients atteint d'un myélo... - HTML (w)

2019.05.21 | 20:23 | Share History / Voting Rights and Number of Shares

puce Information concerning the total number of voting rights and shares - HTML (w)

2019.05.21 | 20:23 | Share History / Voting Rights and Number of Shares

puce Informations relatives au nombre total de droits de vote et d'actions - HTML (w)

2019.05.07 | 15:00 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission - HTML (w)

2019.05.07 | 15:00 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) approuvé dans le traitement de l'asthme sévère par la Commission européenne - HTML (w)

2019.04.30 | 18:00 | Annual General Meeting / AGM

puce Sanofi: Annual General Meeting of April 30, 2019 - HTML (w)

2019.04.30 | 18:00 | Annual General Meeting / AGM

puce Sanofi : Assemblée Générale Annuelle du 30 avril 2019 - HTML (w)

2019.04.27 | 01:20 | Permanent Information Releases / General Company News

puce Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization - HTML (w)

2019.04.27 | 01:20 | Permanent Information Releases / General Company News

puce Sanofi : La FDA approuve Praluent® (alirocumab) dans la prévention du risque d'infarctus du myocarde, d'accident vasculaire cérébral et d'angor instable nécessitant une hospitalisation - HTML (w)

2019.04.26 | 22:00 | Permanent Information Releases / General Company News

puce ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2680